Rekvina Laboratories Ltd (526075)
சுருக்கம்
The board meets on 13 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 13 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 13 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 1 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 13 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Rekvina Laboratories Ltd-இன் இயக்குநர் குழுக் கூட்டம் 13 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, Rekvina Laboratories' revenue was ₹0.7 Cr, and net profit ₹-0.1 Cr (a bigger loss than a year earlier); the operating margin was -18.0%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.7 | — | -7.2% |
| செயல்பாட்டு லாபம் | ₹-0.1 | நஷ்டம் அதிகரித்தது | நஷ்டம் அதிகரித்தது |
| நிகர லாபம் | ₹-0.1 | நஷ்டம் அதிகரித்தது | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -0.20 | நஷ்டம் அதிகரித்தது | நஷ்டம் அதிகரித்தது |
| செயல்பாட்டு லாப வரம்பு | -18.0% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Rekvina Laboratories has announced a temporary shutdown of the manufacturing facility of its wholly owned subsidiary, Radiant Parenterals Limited, effective October 28, 2026. The shutdown is undertaken to conduct renovation and upgradation works, as well as to install an additional vial manufacturing line. The exact capex cost, capacity increase, and project completion timeline were not disclosed. This temporary halt comes as the company operates on a micro scale with TTM revenue of Rs 2 Cr and negative net worth.
- Facility shutdown effective from October 28, 2026
- Undertaken at wholly owned subsidiary Radiant Parenterals Limited
- Scope includes facility renovation, upgradation, and installing an additional vial manufacturing line
- Capex amount, targeted capacity, and expected downtime duration were not disclosed
Rekvina Laboratories has appointed Mr. Subrata Samanta as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective October 7, 2026. Mr. Samanta brings over 20 years of experience in finance, costing, and budgeting, having worked at companies including GNFC, Lupin, and Glenmark. This leadership appointment comes at a crucial time as Rekvina operates at micro-scale, generating Rs 2 Cr in TTM revenue with negative net worth (-Rs 1 Cr) and operating losses.
- Appointment of Mr. Subrata Samanta as CFO and KMP effective 07-10-2026
- Candidate brings 20+ years of experience across finance, costing, and ERP implementations
- Board meeting commenced at 06:50 p.m. and concluded at 7:15 p.m. on October 7, 2026
Rekvina Laboratories has announced the resignation of its Managing Director, Mr. Amit Shah, effective September 11, 2026, citing personal reasons and commitments. Additionally, the Board approved shifting the company's registered office within Vadodara effective September 23, 2026. The micro-cap pharmaceutical company operates with a TTM revenue of Rs 2 Cr and negative net worth of Rs -1 Cr.
- Resignation of Managing Director Mr. Amit Shah noted, effective from 11.09.2026
- Reason cited for MD resignation is personal reasons and personal commitment
- Shift of registered office within Vadodara approved with effect from 23.09.2026
- Board meeting commenced at 06:30 pm and concluded at 07:30 pm on 23-09-2026
Rekvina Laboratories Ltd responded to a BSE surveillance query dated August 14, 2026, regarding significant movement in its share price. The company clarified that it has no undisclosed price-sensitive information, developments, or impending announcements that would impact its stock price. Management stated that all material events have been disclosed per SEBI (LODR) Regulations and the price and volume movement is purely market-driven. Financially, the micro-cap pharma company generated TTM revenue of Rs 2 Cr with negative net worth of Rs -1 Cr.
- Clarification submitted on August 14, 2026, in response to BSE query L/SURV/ONL/PV/SJ/2026-2027/4138
- Company confirmed zero undisclosed price-sensitive information or pending material announcements
- Stated that recent share price and trading volume changes are purely market-driven
- Promoter holding stands at 41.3% with a market capitalization of Rs 32 Cr
Rekvina Laboratories reported a net loss of Rs 12.05 Lacs for the quarter ended June 30, 2026, widening from a loss of Rs 3.54 Lacs in the year-ago period. While revenue from operations grew to Rs 66.85 Lacs from zero in Q1 FY26, it declined sequentially from Rs 72.36 Lacs in Q4 FY26. Total expenses of Rs 78.90 Lacs outpaced income, primarily due to stock-in-trade purchases of Rs 69.76 Lacs. The company also appointed Executive Director Surbhit Shah as the new Chairman of the Board.
- Net loss widened to Rs 12.05 Lacs in Q1 FY27 compared to a loss of Rs 3.54 Lacs in Q1 FY26
- Revenue from operations stood at Rs 66.85 Lacs, up from Nil in the corresponding quarter last year
- Total expenses rose to Rs 78.90 Lacs, with stock-in-trade purchases accounting for 88% of total costs
- Earnings Per Share (EPS) remained negative at -Rs 0.20 for the quarter
- Executive Director Surbhit Shah appointed as Chairman effective August 13, 2026
Rekvina Laboratories has approved the allotment of 50.88 lakh equity shares at ₹10 per share to acquire 100% of Radiant Parenterals Limited and raise cash. The acquisition is valued at ₹4.63 crore via a share swap, while ₹0.46 crore was raised through a cash allotment. This is a transformative deal as Radiant Parenterals reported FY25 revenue of ₹31.67 crore, which is approximately 31.7 times Rekvina's TTM revenue of ₹1 crore. Post-acquisition, Radiant becomes a wholly-owned subsidiary, bringing WHO-GMP certified manufacturing capabilities for injectables and syrups into the company.
- Acquisition of 100% stake (18,51,100 shares) in Radiant Parenterals Limited for a total consideration of ₹4.63 crore.
- Radiant Parenterals FY25 revenue stood at ₹31.67 crore, showing massive growth from ₹0.77 crore in FY23.
- Allotment of 46,27,750 shares via share swap and 4,60,000 shares for cash, all at ₹10 per share (including ₹5 premium).
- Target company operates a WHO-GMP & ISO 9001-2015 certified unit in Vadodara specializing in anti-hypertensive and anti-diabetic products.
- Significant increase in promoter-linked shareholding, with two key investors moving from a combined 28.95% to 49.33% stake.
Rekvina Laboratories has scheduled a board meeting on August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position with a negative net worth of Rs 1 Cr and TTM revenue of only Rs 1 Cr. In the previous quarter (March 2026), it reported revenue of Rs 0.72 Cr and a net loss of Rs 0.06 Cr. Investors should watch for any signs of revenue growth or margin improvement to offset the negative ROCE of -333.3%.
- Board meeting scheduled for August 13, 2026, to consider Q1 results
- Trading window for designated persons closed from July 01, 2026
- Company reported a total revenue of Rs 1.27 Cr for the full year FY26
- Net worth remains negative at Rs -1 Cr as per latest available data
- March 2026 quarter revenue stood at Rs 0.72 Cr with a net loss of Rs 0.06 Cr
The open offer for Rekvina Laboratories by Surbhit Mukesh Shah and others concluded with 14,41,863 shares accepted at ₹10 each, totaling ₹1.44 Cr. This acquisition, combined with a share swap agreement (SEPA), will result in the promoter group holding 77.33% of the expanded share capital. The offer price of ₹10 is at a significant discount to the current market price of ₹25.2. The company remains financially stressed with a negative net worth of ₹1 Cr and TTM revenue of only ₹1 Cr.
- 14,41,863 shares accepted in the open offer at a price of ₹10 per share
- Total consideration paid for the open offer shares amounted to ₹1.44 Cr
- Promoter group holding to reach 77.33% of expanded share capital post-transaction
- Public shareholding reduced significantly from 58.70% to 23.00%
- Underlying transaction involves a share swap of 46,27,750 equity shares at ₹10 each
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
